USE OF ZOLEDRONIC ACID AND A RАNK LIGAND INHIBITOR IN THE PALLIATIVE TREATMENT OF CANCERS OF THE PROSTATE WITH BONE METASTASES

In the metastatic patterns of the cancer, the tumor foci are located more frequently in the tubular bones and vertebral column, just less frequently in the bones of the pelvis, and even more rarely in those of the shoulder and skull. Bone pain is usually related to the involvement of the periosteum that has an extensive network of nociceptors. Auxiliary exposures that directly affect the intensity of pain syndrome and the strength of bone structures are used in addition to basic therapy options for cancer of the prostate. Among these agents there are bisphosphonates. Once ingested, bisphosphonates are transported by blood to the areas of active bone tissue rearrangement where they are tightly bound to the mineral matrix. Their administration causes a considerable reduction in pain syndrome, a decrease in the frequency of complications of bone metastases, and an increase in time before a first bone complication. Antiresorptive therapy including particularly zoledronic acid (resorba) or denosumab is a necessary treatment option in the above category of patients with bone metastases.

1. Павленко Н. И., Коршунов Г. В., Попова Т. Н. и др. Метастатическое поражение костной системы. Сиб онкол журн 2011;4:46–8.

2. Rubens R. D., Coleman R. E. Bone metastases. Clinical Oncology. New York: Churchill Livingstone, 1995; p. 643–65.

3. Исакова М. Е., Павлова З. В., Лактионов К. П. Лечение болевого синдрома у онкологических больных. М., 1994.

4. Dijkstra P. D. S. Pathological fracture of long bones due bone metastases. 2001. Chapter 1.

5. Coleman R. E. Skeletal complications of malignancy. Cancer 1997; 80:1588–94.

6. Boissier S., Ferreras M., Peyruchaud O. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949–54.

7. Chirgwin J. M., Guise T. A. Molecular biology of bone metastasis. Mol Canc Ther 2007;6(10);2609–17.

8. Evans C. E., Braidman I. P. Effects of two novel bisphosphonates on bone cells in vitro. J Bone Miner Res 1994;26:95–107.

9. Zometa (zoledronic acid) package insert. East Hanover, New Jersey: Novartis, 2009.

10. Long-term efficacy of zoledronic acid for the prevention оf skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96: 879–82.

11. Roodman G. D., Dougal W. C. RANK ligandas a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34(1):92–101.

12. Fizazi K., Carducci M., Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind stady. Lancet 2011;377: 813–22.

13. Smith M. R., Saad F., Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. Lancet 2012;379 (9810):39–46.